The treatment of primary hyperlipidaemic states is reviewed. While several metabolically distinct forms of hyperlipidaemia exist, it is possible to classify patients into three groups for the purpose of therapy.
Introduction
Evidence has been presented that hyperlipidaemia is one of the major sources of risk of ischaemic heart disease. Preventive measures directed against this risk factor fall into two categories. One is the public health approach, which seeks to shift the frequency distribution of serum lipid levels in the population towards the left, decreasing the proportion of the community whose lipid concentrations lie in the high-risk part of the distribution. The only feasible means of achieving this is dietary, and involves us in providing the public, the food manufacturer and the government with realistic advice on desirable nutritional patterns.
The second category affects us in our directly clinical role and involves the detection of hyperlipidaemia in our patients and their relatives, with a view to optimal treatment. Therapy has to be appropriate to the particular metabolic disorder present: no single measure is effective against all hyperlipidaemic states. As hyperlipidaemia (however defined) is among the commonest of metabolic disorders, we are concerned with potentially large numbers of patients. The clinical and laboratory investigations should therefore be as simple as possible.
Recognition of hyperlipidaemia
Only a minority of hyperlipidaemic patients present with specific diagnostic features such as xanthomas, but it adds only a moment to routine * Present address: Department of Chemical Pathology, St Thomas's Hospital Medical School, London, S.E. 1. examination to feel for tendon xanthomas on the dorsa of the hands and in the Achilles tendons, and to look for cutaneous xanthomas on the knees, elbows and buttocks, and in the palmar creases. An uncommon but characteristic sign is retinal lipaemia. Less exotic signs are corneal arcus and xanthelasmas, which are suggestive of hyperlipidaemia when they occur in young individuals (before age 35) but can occur with apparently normal lipid levels. Severe hypertriglyceridaemia can lead to attacks of acute pancreatitis, and recurrent abdominal pain may be the presenting symptom of this group of metabolic disorders. Gall-stones also occur with abnormal frequency in this group of patients. Abdominal 'angina' is an occasional manifestation.
Hyperlipidaemia may present with rheumatological features. An acute migratory large-joint polyarthritis occurs in patients with severe hypercholesterolaemia, resembling rheumatic fever; the presence of tendon xanthomas, and the family history, suggest the correct diagnosis. Hyperuricaemia is frequently associated with the common endogenous form ofhypertriglyceridaemia and overt gouty arthritis is sometimes seen.
All too often, hyperlipidaemia is first recognized in the course of investigating patients who already have manifest ischaemic heart disease or peripheral vascular disease. This could be regarded as an advanced stage in the natural history of this group of metabolic defects; but there is justification for detecting and treating hyperlipidaemia even at this juncture, for hypercholesterolaemia remains a risk factor for recurrence of new ischaemic events in patients who have experienced myocardial infarction (Coronary Drug Project Research Group, 1974) . Surgical treatment of coronary artery atherosclerosis is now making it possible to relieve myocardial ischaemia in selected patients. It seems appropriate to deal with correctable risk factors in patients so treated.
Another cardiovascular manifestation of severe hypercholesterolaemia is aortic stenosis. Xanthomatous involvement of the valve, or gross atherosclerosis of the ascending aorta can produce valvar or supravalvar stenosis with a pressure gradient; coronary disease may or may not also be present.
Of patients with ischaemic heart disease, 56% were found to have hyperlipoproteinaemia (defined as levels exceeding the 90th percentile) in a recent study (Lewis et al., 1974a) . Similar findings have been obtained in peripheral vascular disease (Lewis et al., 1974b) . Most types of hyperlipoproteinaemia were over-represented in these series compared with apparently-healthy controls. In young patients, up to 80 % may be so affected. In these studies, raised levels of very low density lipoprotein (VLDL, pre-p3-lipoprotein) were the commonest finding, followed by increased concentrations of low density lipoprotein (LDL, P-lipoprotein), and by raised levels of both VLDL and LDL. LDL is the major cholesterolbearing lipoprotein of plasma, while the VLDL carries most of the circulating endogenous triglyceride and also a moderate proportion of the plasma cholesterol.
The forms of hyperlipidaemia accompanying ischaemic heart disease have recently been the subject of important genetic studies (Goldstein et al., 1973; Nikkila and Aro, 1973; Patterson and Slack, 1972) . All have agreed that the commonest heritable disorder of lipid metabolism in such patients is an indeterminate one in which members of affected families may show raised levels of either VLDL or LDL or of both lipoproteins, 'multiple-type' hyperlipoproteinaemia or familial combined hyperlipidaemia. In terms of serum lipids, increased concentrations of both cholesterol and triglyceride are commoner than elevation of either lipid alone.
Screening for hyperlipidaemia
Many hyperlipidaemic individuals are detected as a result of screening procedures, either in the course of 'health-screening' or of 'profiling' of patients. An important aspect of the investigation of hyperlipidaemic patients is the measurement of serum lipid levels in their accessible first-degree relatives. The early diagnosis of hyperlipidaemia may be so achieved.
Whole-population screening for heart disease risk factors has its advocates. Further evidence is desirable as to the benefits of this approach, and at the practical level, facilities do not exist at present for the management of large numbers of hyperlipidaemic individuals. But it is possible to define population groups in whom risk factor screening on a relatively modest scale is possible. Amongst these are patients developing cardiac or peripheral ischaemia, especially before the age of 60, and their first-degree relatives. Patients prone to secondary hyperlipidaemia include those with diabetes, gout and chronic renal failure. There is evidence that the frequency of ischaemic heart disease is grossly increased in such conditions, and correction of associated hyperlipidaemia and hypertension is indicated. Evidence is presented elsewhere in this symposium that the presence of multiple risk factors leads to a striking increase in proneness to ischaemic heart disease. A convincing case can therefore be made for assessing serum lipid levels in patients with hypertension.
The common hyperlipidaemias (Fredrickson and Levy, 1972; Beaumont et al., 1970; Lewis, 1976) .
Definition of the upper limit of normality is necessary for clinical purposes, but is a somewhat arbitrary matter. At the author's lipid clinic the cutoff points are the 90th percentiles for apparently healthy adults aged 20-39 years. For cholesterol, the level is 250 mg/100 ml (6 5 mmol/1) in both sexes. The upper limit for triglyceride in men is 2-1 mmol/1 (185 mg/100 ml) and in women 1-5 mmol/1 (135 mg/100 ml). Blood samples are drawn without venous stasis, with the subject sitting quietly, having fasted for 12-14 hr. For baseline measurements, the patient should be on his normal diet for at least 2 weeks, and should not have taken lipid-active drugs for a month. Lipid studies should be deferred for 3 months after major illness.
The initial classification distinguishes primary and secondary hyperlipidaemias. Clinical examination and simple laboratory investigations usually suffice for this purpose. Common underlying causes are hypothyroidism, diabetes, alcoholism, cholestasis, uraemia, nephrotic syndrome and gout. No fundamental classification of primary hyperlipoproteinaemias is yet possible. In order to provide optimal therapy of primary hyperlipidaemic states, these must be classified into a minimum of three categories; the first two, and possibly all of these are genetically and metabolically heterogeneous.
(1) The hyper-/J-lipoproteinaemia group (type Ha) This is characterized by hypercholesterolaemia with normal triglyceride levels, and is a common disorder. In most patients hyper-o-lipoproteinaemia appears to be the result of the interaction between multiple genes and environmental factors, of which diet is likely to be important ('polygenic type'). Much more rarely it is due to a single dominant gene (monogenic hyper-,B-lipoproteinaemia). Both forms are undoubted risk factors for ischaemic heart disease. At least 50 % of men with the latter disorder develop ischaemic heart disease by the age of 50 years (Slack, 1969) , although it appears somewhat less hazardous in women. The concentration of 0-lipoprotein in the arterial intima is increased several fold, paralleling plasma levels (Onitiri et al., 1976) . Ischaemic heart disease presents at a significantly younger age in patients with this disorder than in those with normal serum lipoproteins (Lewis et al., 1974a) and ischaemic ECG changes are common even in asymptomatic individuals (Carlson, Ekelund and Olsson, 1975) .
In many respects these forms of hyper-3-lipoproteinaemia differ. Physical signs in the polygenic variety are limited to xanthelasmas and corneal arcus, while patients with the monogenic form commonly develop tendon xanthomas. In the homozygous state, and in severely affected heterozygotes, the latter form is also characterized by cutaneous xanthomas (flattened, planar lesions on extensor surfaces) and by aortic stenosis. When hypertriglyceridaemia is accompanied by normal or modestly-increased cholesterol levels, the underlying lipoprotein abnormality is likely to be an increase in VLDL levels (type IV). This is the commonest form of endogenous hypertriglyceridaemia. In patients with severe hypertriglyceridaemia, elevated VLDL concentration is sometimes associated with chylomicronaemia (type V). Other variants of endogenous hypertriglyceridaemia are those in which both triglyceride and cholesterol levels are substantially increased. This is most often due to elevation of both VLDL and LDL concentration (type 1Ib); less often, there is an accumulation in plasma of partly delipidated 'remnants' of VLDL and chylomicra (type III). In this disorder, it is usual to find rounded tuberous xanthomas over the elbows, and orange-coloured planar xanthomas in the palmar creases.
In the diagnosis of these disorders, it is necessary to characterize the lipoprotein pattern underlying the hyperlipidaemia; this is principally to exclude the rare group 3 disorder in which chylomicronaemia is the typical finding. The simplest laboratory method for making this distinction is the 'stored serum test'.
After hypertriglyceridaemic serum has stood for 18 hr at 40C, it may show a variety of appearances.
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Chylomicra float to the surface, producing a creamy upper layer with clear subnatant: this is the characteristic appearance of exogenous hypertriglyceridaemia (group 3). The particles containing endogenous triglyceride do not float under these circumstances, hence the sample remains diffusely lactescent (turbid), although sometimes with an additional creamy upper layer. Lipoprotein electrophoresis will also permit recognition of the various forms of hypertriglyceridaemia.
In some patients, endogenous hypertriglyceridaemia appears to be due to overproduction of VLDL, while others show defective removal of triglyceride from plasma. Hyperinsulinism is not a constant feature of the disorder but it is widely believed that at least in a subgroup of patients with endogenous hypertriglyceridaemia, excessive secretion of VLDL by the liver is caused by the insulin excess. There is little evidence that dietary carbohydrate plays a role in the pathogenesis of this group of disorders.
(3) Exogenous hypertriglyceridaemia
Severe hypertriglyceridaemia and relatively moderate hypercholesterolaemia are the usual findings in this condition, the excessive amounts of plasma lipids being transported entirely or chiefly in chylomicra (type I hyperlipoproteinaemia). As mentioned earlier, this is most readily diagnosed by the appearance of stored serum: a floating creamy layer with clear subnatant is characteristic. The electrophoretic pattern of serum lipoproteins is often diagnostic.
Patients usually present in infancy or childhood but the diagnosis may not be made until adult life. Attacks of abdominal pain are the commonest presenting feature, the other common manifestation being eruptive xanthomas.
The condition is due to recessively-inherited deficiency of the enzyme lipoprotein lipase, present chiefly in muscle and adipose tissue; this enzyme hydrolyses circulating triglyceride permitting its uptake from plasma. Dietary fat therefore accumulates in plasma, and lipaemia is much diminished within 3-5 days of instituting a fat-free diet. Lipoprotein lipase may be assayed in plasma after injection of heparin, which releases it into the circulation.
Despite the severity of the hyperlipidaemia in this disorder, there is no evidence that it predisposes to premature vascular disease. The purpose of treatment is to avert pancreatitis and xanthomatosis.
Treatment of hyperlipidaemias (Tabaqchali et al., 1974; Lewis, 1976 The treatment of exogenous hypertriglyceridaemia is by a diet low in ordinary fats. Adults most often tolerate 20-25 g fat/day. The diet can be made more palatable by addition of medium chain triglyceride, which is not transported in chylomicra.
